1. 2366 Metronomic capecitabine and bevacizumab is an active combination in patients with relapsed peritoneal pseudomyxoma. (September 2015) Authors: Maggi, C.; De Braud, F.; Di Bartolomeo, M.; Perrone, F.; Tamborini, E.; Milione, M.; Deraco, M.; Kusamura, S.; Baratti, D.; Berenato, R.; Caporale, M.; Consonni, P.V.; Niger, M.; Bossi, I.; Leo, E.; Pelosi, G.; Pietrantonio, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S458 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment. (21st November 2013) Authors: Coronel, J.; Roper, M. H.; Herrera, C.; Bonilla, C.; Jave, O.; Gianella, C.; Sabogal, I.; Huancaré, V.; Leo, E.; Tyas, A.; Mendoza‐Ticona, A.; Caviedes, L.; Moore, D. A. J.; Drancourt, M. Journal: Clinical microbiology and infection Issue: Volume 20:Number 6(2014:Jun.) Page Start: 536 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗